These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32708766)

  • 1. Poor Sleep Quality, Depression and Social Support Are Determinants of Serum Phosphate Level among Hemodialysis Patients in Malaysia.
    Ng ESY; Wong PY; Kamaruddin ATH; Lim CTS; Chan YM
    Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32708766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status.
    Lopes AA; Tong L; Thumma J; Li Y; Fuller DS; Morgenstern H; Bommer J; Kerr PG; Tentori F; Akiba T; Gillespie BW; Robinson BM; Port FK; Pisoni RL
    Am J Kidney Dis; 2012 Jul; 60(1):90-101. PubMed ID: 22385781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants.
    Van Camp YP; Vrijens B; Abraham I; Van Rompaey B; Elseviers MM
    J Nephrol; 2014 Dec; 27(6):673-9. PubMed ID: 24563270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidisciplinary education approach to optimize phosphate control among hemodialysis patients.
    Chan MW; Cheah HM; Mohd Padzil MB
    Int J Clin Pharm; 2019 Oct; 41(5):1282-1289. PubMed ID: 31302884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
    Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
    Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of phosphate abnormalities in hemodialysis patients: Findings from Malaysia.
    Mohamed Koya SNM
    Saudi J Kidney Dis Transpl; 2019; 30(3):670-677. PubMed ID: 31249232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and Rationale of HiLo: A Pragmatic, Randomized Trial of Phosphate Management for Patients Receiving Maintenance Hemodialysis.
    Edmonston DL; Isakova T; Dember LM; Brunelli S; Young A; Brosch R; Beddhu S; Chakraborty H; Wolf M
    Am J Kidney Dis; 2021 Jun; 77(6):920-930.e1. PubMed ID: 33279558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis.
    Bhargava R; Kalra PA; Hann M; Brenchley P; Hurst H; Hutchison AJ
    BMC Nephrol; 2019 Feb; 20(1):37. PubMed ID: 30717691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily dietary phosphorus intake variability and hemodialysis patient adherence to phosphate binder therapy.
    Tao X; Zhang H; Yang Y; Zhang C; Wang M
    Hemodial Int; 2019 Oct; 23(4):458-465. PubMed ID: 31328873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum potassium and handgrip strength as predictors of sleep quality among hemodialysis patients in Malaysia.
    Ling LL; Chan YM; Mat Daud Z'
    Asia Pac J Clin Nutr; 2019; 28(2):401-410. PubMed ID: 31192570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperphosphataemia: treatment options.
    Malberti F
    Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial.
    Yin J; Yin J; Lian R; Li P; Zheng J
    BMC Nephrol; 2021 Jul; 22(1):243. PubMed ID: 34210293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis.
    Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ
    Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
    Shigematsu T; Une Y; Ikejiri K; Kanda H; Fukagawa M; Akizawa T
    Am J Nephrol; 2021; 52(6):496-506. PubMed ID: 34098559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorus Counting Table for the control of serum phosphorus levels without phosphate binders in hemodialysis patients.
    Bertonsello-Catto VR; Lucca LJ; da Costa JAC
    Clin Nutr ESPEN; 2019 Aug; 32():153-157. PubMed ID: 31221281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial.
    Wald R; Rabbat CG; Girard L; Garg AX; Tennankore K; Tyrwhitt J; Smyth A; Rathe-Skafel A; Gao P; Mazzetti A; Bosch J; Yan AT; Parfrey P; Manns BJ; Walsh M
    Clin J Am Soc Nephrol; 2017 Jun; 12(6):965-973. PubMed ID: 28550080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of iron as a new type of phosphate binder in hemodialysis patients.
    Kuroda S; Komori M; Nagamatsu K; Ninomiya R; Maejima K; Hasegawa K; Samejima M; Kuroda M; Fujimori H; Kasai M
    Nihon Jinzo Gakkai Shi; 1995 Aug; 37(8):468-73. PubMed ID: 7563956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Medical Nutrition Intervention on the Management of Hyperphosphatemia in Hemodialysis Patients with Stage 5 Chronic Kidney Disease: A Case Series.
    Moroșan E; Popovici V; Elian V; Dărăban AM; Rusu AI; Licu M; Mititelu M; Karampelas O
    Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.